Xenon Pharmaceuticals (XENE) Reports Q1 Loss of $0.42, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 4:01 PM EDTTopline Data from XEN1101 Phase 2b X-TOLE Clinical Trial Anticipated by End of Third Quarter of 2021
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make excellent progress across both our proprietary and partnered... More
